|
|
Volumn 34, Issue 3, 2000, Pages 737-740
|
|
Irinotecan - A case study for the transition from accelerated approval to traditional approval
a
|
|
Author keywords
Accelerated approval; Colorectal cancer; Food and Drug Administration; Irinotecan; Surrogate marker
|
|
Indexed keywords
AMIFOSTINE;
ANTINEOPLASTIC AGENT;
BICALUTAMIDE;
CAPECITABINE;
CELECOXIB;
CYTARABINE;
DOCETAXEL;
DOXORUBICIN;
FLUOROURACIL;
IRINOTECAN;
RAZOXANE;
ARTICLE;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLORECTAL CANCER;
DISEASE MARKER;
DRUG APPROVAL;
DRUG SCREENING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
METASTASIS;
PRIORITY JOURNAL;
|
|
EID: 0033842452
PISSN: 00928615
EISSN: None
Source Type: Journal
DOI: 10.1177/009286150003400309 Document Type: Article |
|
Times cited : (1)
|
|
References (5)
|
